<DOC>
	<DOCNO>NCT00016315</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , carboplatin , paclitaxel , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine combination chemotherapy radiation therapy treat patient stage IIIA stage IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine , Carboplatin Paclitaxel Plus Radiation Therapy Treating Patients With Stage IIIA IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) gemcitabine administer carboplatin thoracic radiotherapy follow adjuvant gemcitabine carboplatin patient stage IIIA IIIB non-small cell lung cancer . - Determine MTD gemcitabine paclitaxel administer thoracic radiotherapy follow adjuvant gemcitabine carboplatin patient . OUTLINE : This multicenter , dose-escalation study gemcitabine paclitaxel . Patients sequentially assign 1 3 treatment regimen . - Regimen A : Patients receive gemcitabine IV 30-60 minute day 1 , 8 , 22 , 29 , 43 thoracic radiotherapy daily 5 day week 7 week begin day 1 . - Regimen B ( close accrual 5/13/03 ) : Patients receive gemcitabine thoracic radiotherapy regimen A carboplatin IV 30 minute day 1 , 8 , 22 , 29 , 43 . - Regimen C : Patients receive gemcitabine thoracic radiotherapy regimen A paclitaxel IV 1 hour day 1 , 8 , 22 , 29 , 43 . At 3 week completion chemoradiotherapy , patient receive adjuvant gemcitabine IV 30-60 minute day 71 , 78 , 92 , 99 carboplatin IV 30 minute day 71 92 . The first 6 patient enrol receive regimen A determine safety initial dose gemcitabine . After completion regimen A , cohorts 3-6 patient receive escalate dos gemcitabine regimen B ( close accrual 5/13/03 ) maximum tolerate dose ( MTD ) determine . In separate sequence , cohorts 3-6 patient receive alternate escalate dos gemcitabine paclitaxel regimen C MTD determine . The MTD define dose precede least 3 6 patient experience dose-limiting toxicity . Patients follow 3 month , 6 month , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A maximum 78 patient accrue study within 29 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locoregionally advanced nonsmall cell lung cancer meet one follow stag criterion : Medically inoperable stage IIIA Unresectable stage IIIA IIIB Measurable disease threedimensional planning CT scan No postresection intrathoracic tumor recurrence No pleural effusion chest xray except occur attempted thoracotomy invasive thoracic procedure No evidence small cell histology No evidence hematogenous distant metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Absolute granulocyte count least 2,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL Serum glutamate oxaloacetate transaminase ( SGOT ) great 1.5 time upper limit normal ( unless cause documented benign disease ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No myocardial infarction within past 6 month No symptomatic heart disease , include angina , congestive heart failure , uncontrolled arrhythmia Pulmonary : Forced expiratory volume ( FEV ) _1 great 1,000 mL Other : No invasive malignancy within past 3 year except nonmelanoma skin cancer No weight loss 10 % 3 month prior diagnosis Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic neck radiotherapy Surgery : See Disease Characteristics No prior complete subtotal tumor resection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>